When is the earnings report for Evgen? This is a question we get a lot from our investors. While it is important to check for earnings surprises, it is also important to keep a close eye on the stock’s future. After all, there is a lot of risk associated with trading EVG. The company is a clinical stage drug developer focused on developing sulforaphane-based medicines and products. Its lead product, SFX-01, is currently in Phase II clinical trials for metastatic breast cancer and glioblastoma. It also has several compounds in preclinical stages that are aimed at treating haematological malignancies.
In addition to the GAAP financial measures, EVgo also uses non-GAAP financial measures to evaluate the company’s performance. These metrics are not considered a substitute for GAAP financial information, but rather, they are designed to enhance the ability of management to compare past performance to current levels. These financial measures exclude certain expenses and items that are not indicative of EVgo’s core business. EVgo’s management believes that these metrics are helpful to investors and provide a more complete understanding of its financial performance.
EVG holds a dominant position in the wafer bonder market and is an expert in advanced packaging and NIL. This dominant position has contributed to its financial performance in 2009, as orders and revenues continued to grow. The company also recently formed a new research consortium with Fraunhofer-IZM to drive 3D IC manufacturing costs down. This collaboration has proven to be beneficial to the company, as the EV Group has successfully applied its technologies to a variety of applications.